Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

BofA raises Apollo Medical stock to Buy, sees 40% upside

EditorRachael Rajan
Published 22/02/2024, 14:54
Updated 22/02/2024, 14:54
© Reuters.

On Thursday, BofA Securities adjusted its stance on Apollo Medical Holdings (NASDAQ:AMEH), upgrading the stock from Neutral to Buy and raising the price target to $55.00 from the previous $44.00. The decision comes as the firm anticipates the company to experience significant revenue growth in the near future.

Apollo Medical Holdings is expected to double its revenue over the next few years, driven by the conversion of its RKK license and pending mergers and acquisitions. The company's growth prospects are also bolstered by new organic contract wins, strategic tuck-in deals, a reduction in tax rates, and the elimination of one-time headwinds.

The upgrade reflects BofA Securities' confidence in the company's growth trajectory and its ability to outperform market expectations. The firm's new price objective suggests a substantial 40% upside from the current levels.

According to BofA Securities, Apollo Medical's earnings before interest, taxes, depreciation, and amortization (EBITDA) are projected to surpass the consensus estimates for the years 2024 through 2026.

InvestingPro Insights

As Apollo Medical Holdings (NASDAQ:AMEH) receives an optimistic outlook from BofA Securities, with expectations of significant revenue growth, InvestingPro data supports this positive sentiment. The company's market capitalization stands at $1.91 billion, reflecting a solid presence in the healthcare sector. Moreover, the company's revenue over the last twelve months as of Q3 2023 is reported at $1.33 billion, with a notable growth rate of 27.06%. This aligns with the forecasted expansion BofA Securities anticipates.

One of the InvestingPro Tips that resonates with the upgraded status is the company's strong return over the last three months, which is at 15.84%. This performance could instill further confidence in investors looking for upward trends. Additionally, Apollo Medical is trading near its 52-week high, at 94.95% of the peak value, which may be indicative of sustained investor interest and market momentum.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Furthermore, analysts on InvestingPro predict that the company will be profitable this year, reinforcing BofA Securities' upgrade. For investors seeking more in-depth analysis, there are additional InvestingPro Tips available, including insights into Apollo Medical's debt levels, liquidity, and long-term profitability. To uncover these valuable tips, visit https://www.investing.com/pro/AMEH and consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. There are 6 more InvestingPro Tips waiting to help you make informed decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.